Cartesian Therapeutics’ Descartes-08 Observed To Provide Deep And Sustained Benefits Through Month 12 After A Single Course Of Therapy In Phase 2B Myasthenia Gravis Trial
April 8 (Reuters) - Cartesian Therapeutics Inc RNAC.O:
CARTESIAN THERAPEUTICS’ DESCARTES-08 OBSERVED TO PROVIDE DEEP AND SUSTAINED BENEFITS THROUGH MONTH 12 AFTER A SINGLE COURSE OF THERAPY IN PHASE 2B MYASTHENIA GRAVIS TRIAL
CARTESIAN THERAPEUTICS INC - PHASE 3 AURORA TRIAL ON TRACK TO DOSE FIRST PATIENT IN 2Q25
CARTESIAN THERAPEUTICS-SAFETY PROFILE CONSISTENT WITH PREVIOUSLY REPORTED DATA AND CONTINUES TO SUPPORT OUTPATIENT ADMINISTRATION
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Intel Foundry Gains ‘High-Profile’ Customer, Tesla Becomes First Major Customer for 14A Technology

Anthropic Eclipses OpenAI in Secondary Market as Valuation Hits $1 Trillion Milestone, Is the AI Market Overheating Now?

Robinhood Stock Predictions: Can HOOD Reach the $1,000 Milestone?

Tesla Officially Announces. Third-Generation Humanoid Robot to Debut Mid-Year, Mass Production to Start in Third Quarter

Intel Better-Than-Expected Earnings Released, Stock Surges 20% After-Hours, AI Computing Power Enters CPU Moment?

Tradingkey








